Open AccessImmediate-release tofacitinib reduces insulin resistance in non-diabetic active rheumatoid arthritis patients: A single-center retrospective study
Author(s) -
ChrongReen Wang,
HungWen Tsai
Publication year - 2022
Publication title -
world journal of diabetes
Language(s) - Uncategorized
Resource type - Journals
ISSN - 1948-9358
DOI - 10.4239/wjd.v13.i6.454
Subject(s) - medicine , tofacitinib , rheumatoid arthritis , insulin resistance , proinflammatory cytokine , janus kinase , tocilizumab , population , gastroenterology , diabetes mellitus , immunology , insulin , pharmacology , endocrinology , cytokine , inflammation , environmental health
An increased risk of insulin resistance (IR) has been identified in rheumatoid arthritis (RA), a chronic inflammatory disorder with elevated levels of pathogenic cytokines. Biologics targeting proinflammatory cytokines can control the disease and improve insulin sensitivity in RA. Although Janus kinase (JAK) signaling can regulate cytokine receptors and participate in RA pathogenesis, it remains to be elucidated whether there is a reduction of IR in such patients under JAK inhibitor (JAKi) therapy.